Frequently Asked Questions

No, all RGCC tests are currently ordered by registered practitioners. Our Customer Relations team is happy to provide you with practitioners in your area. Please contact us.

Our tests can be utilized for all types of hematological and solid cancers, at various stages, outside of brain tumors because of the blood brain barrier not allowing the cells into general circulation.

Please see our published research articles, here: https://rgcc-international.com/published-articles/

To order an RGCC test or therapy, the doctor must be registered with RGCC.  To become an RGCC Registered Practitioner, please have your doctor visit https://myrgcc.com/contact-us/ and someone from our RGCC College team will contact them with next steps.

All test results are posted to your RGCC Practitioner's Portal approximately 2 weeks from the time the blood arrives at the lab (and 3-4 weeks for ArrayCGH RGCC tests). Once your results are available, your practitioner will reach out to you to review and interpret your results. 

All our registered practitioners are trained to guide you through the testing options and will make recommendations that are right for you.

The power of our monitoring tests is they give you a measure of whether a treatment option is working or not so you can change course if needed. Along with the Onconomics panels which provide information about personalized treatment options, you have information on options that may be more effective for you.

Each patient is unique. How often you should see your practitioner must be decided in consultation with them after they have reviewed your case. Although this timing may vary based on factors such as treatment options, within our process, monitoring is recommended every 3 months with active cancer to monitor effectiveness of treatments, and every 6-12 months in remission to monitor for early signs of recurrence as part of your Recurrence Prevention Program.

Even when you receive the “all clear” from your Oncologist, there may be CSCs (Circulating Stem Cell-like Cells) also known as TICs (Tumor Initiating Cells) still active and in circulation but at a level below the sensitivity of standard-of-care monitoring tests, such as imaging and physiological cancer marker testing. 

This means active cancer cells may be present, but they cannot be detected via traditional means until the cancer has grown big enough to be detected again. This leaves you vulnerable and without treatment because in the standard-of-care model, if you can’t see it, you can’t treat it, enabling the cancer to come back.

TIC monitoring with our Oncotrace and Oncotrail RGCC allows you to monitor these cells on a microscopic level allowing you to continue care until these cells are no longer active or if in remission, allowing you to see new activity as soon as it starts.

Cancer is often more aggressive when there is a recurrence. This highlights the importance of having a Recurrence Prevention Program once the cancer has gone into remission or as part of your post-treatment aftercare. 

Standard-of-care monitoring tests are not sensitive enough to detect early-stage recurrence activity. This allows cancer to take hold before it is detected, making it harder to treat. If you can’t see it, you can’t treat it. 

At RGCC, our Oncocount, Oncotrace, and Oncotrail RGCC monitoring tests detect the presence of cancer cells on a microscopic level, allowing for the earliest detection and treatment of recurrence allowing for a proactive, rather than reactive approach to care.

No. Cancer is not contagious and cannot be passed from one person to another.

Our team at RGCC North America is happy to provide you with a list of registered practitioners. Simply fill out the contact form and our team will begin building your personalized referral list.

Blood draw kits can only be ordered by our registered practitioner. Simply fill out the contact form and our team will begin building your personalized referral list.